CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10%

CEL-SCI Corporation (NYSE:CVM) today announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*. The findings were presented by the Company’s Chief Scientific Officer and developer of Multikine, Dr. Eyal Talor, during a keynote address at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy.

The presentation highlights how pre-surgical patient stratification addresses a long-standing limitation in head and neck cancer management, where patient risk assessment traditionally relies on post-operative pathological evaluation.